TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A federal agreement tied to CVS’s $315 million opioid settlement requires the pharmacy chain to block controlled-substance prescriptions from certain prescribers. The requirements do not expressly mandate tracking what happens to their patients afterward, leaving open whether patients reach safer care or face treatment interruptions.
CVS must block controlled-substance prescriptions from certain prescribers under a memorandum accompanying its $315 million opioid settlement, but the agreement does not expressly require the company to track the health outcomes of patients affected by those restrictions. The gap matters because stopping potentially unsafe dispensing may reduce exposure to dangerous drugs, while patients may still need pain care, withdrawal management or treatment for opioid use disorder.
The settlement resolves federal allegations involving unlawful dispensing and false claims, according to the source report. CVS did not admit liability. The accompanying Drug Enforcement Administration memorandum sets out two categories of prescriber blocks: prescriptions from clinicians whose DEA registration or state license has been suspended or revoked, and prescriptions from clinicians whose prescribing concerns remain unresolved after review. In the latter category, CVS must block the prescriber across its retail pharmacies unless the law prohibits it.
The memorandum also requires CVS to report blocked prescribers, but it does not expressly require an assessment of what happens to the patients who had received prescriptions from them. The commentary by Alex Smolak, PhD, published by MedPage Today on October 21, says a similar approach appeared in CVS’s 2022 multistate settlement. The latest agreement therefore reinforces an existing policy rather than establishing a wholly new one.
Smolak argues that evaluating the policy should include patient care after a block. People treated by the same prescriber can have different conditions and treatment histories. Some may benefit from stopping dangerous dispensing; others may need a new clinician to reassess their care, address physical dependence, or provide treatment for opioid use disorder. A pharmacy restriction alone does not establish that those needs have been met.
Patient Care After a CVS Block
The policy’s immediate aim is to prevent dispensing linked to prescribers considered unsafe, but reduced dispensing is not the same as improved health. After a block, a patient might find appropriate care elsewhere, continue a risky regimen through another pharmacy, or experience an extended gap in treatment. Those outcomes carry different implications for safety, and pharmacy records alone may not reveal which occurred.
Smolak points to federal guidance and prior research as reasons to examine treatment disruptions carefully. The FDA has warned of severe withdrawal, uncontrolled pain and suicide after rapid opioid reduction or abrupt discontinuation in physically dependent patients. CDC guidance cautions against rigid restrictions and abandoning patients. A large observational study in JAMA associated tapering among people on stable, long-term, higher-dose opioids with increased rates of overdose and mental-health crises.
Those findings do not show that CVS prescriber blocks cause the same outcomes. A pharmacy block differs from a dose taper, and patients may receive care elsewhere. The evidence instead identifies possible harms of treatment interruption that an evaluation should consider alongside any reduction in unsafe dispensing.
As an affiliate, we earn on qualifying purchases.
What the Settlement Requires
The settlement and its memorandum address the dispensing of controlled substances at CVS pharmacies. The specified restrictions apply when a prescriber’s DEA registration or state license has been suspended or revoked, and when prescribing concerns remain unresolved after review, subject to legal limits. The memorandum requires reporting on blocked prescribers, but, as described in the source report, does not expressly require monitoring patients’ subsequent health outcomes.
The October agreement follows a 2022 multistate settlement that included comparable provisions. Smolak’s MedPage Today commentary is not a finding that the new restrictions have harmed patients. It proposes extending reporting and evaluation so that the effects of blocks can be considered beyond the initial reduction in dispensing.
“Stopping harmful prescribing and reducing the patient’s overall risk belong in the same intervention.”
— Alex Smolak, PhD, in a MedPage Today commentary
pain relief medication for opioid dependence
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Patient Outcomes Remain Unmeasured
The source report does not provide patient-level outcome data after CVS blocks, so it is not yet clear how often patients transition to safer care, continue treatment elsewhere, or experience an interruption. It also does not describe a requirement in the memorandum to link blocked prescribers with subsequent patient records.
Any future study would face limits. Patients of blocked prescribers may already have heightened risks because of their health conditions or the prescribing concerns that triggered review. An adverse event after a block would not, by itself, show that the restriction caused it. Insurance claims may miss pain, functioning, care outside coverage and treatment obtained in other settings; clinical records and patient accounts could add information.
medication-assisted treatment for opioid use disorder
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Researchers Could Track Care
Smolak proposes a focused, independent evaluation, potentially beginning with the population covered by one insurer. Researchers could link CVS prescriber-block dates with pharmacy and medical claims, identify patients who had filled opioid prescriptions at CVS from those prescribers, and follow their care across settings. Possible measures include treatment gaps, later dispensing and emergency visits, compared with carefully selected patients and prior trends.
The proposal is an evaluation approach, not a study already required by the settlement or a confirmed research plan. Researchers would need to account for patients’ circumstances before a block and recognize that claims data provide an incomplete picture. Such work could help establish whether restrictions are followed by safer care and fewer adverse outcomes, while distinguishing those results from treatment displacement or loss of care.
prescription drug monitoring devices
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What does the CVS settlement require the pharmacy chain to block?
The accompanying DEA memorandum requires CVS to block controlled-substance prescriptions from prescribers whose DEA registration or state license has been suspended or revoked. It also requires blocks across CVS retail pharmacies when prescribing concerns remain unresolved after review, unless the law prohibits the block.
Does the agreement require CVS to track patients after a prescriber is blocked?
According to the source report, the memorandum requires reporting of blocked prescribers but does not expressly require assessment of those prescribers’ patients’ later health outcomes.
Does the reporting show that patients have been harmed by the blocks?
No. The commentary discusses possible consequences of treatment interruption and calls for evaluation; it does not present evidence that CVS blocks caused harm to patients.
What does the commentary propose measuring?
It proposes following patients across care settings and examining treatment gaps, later dispensing and emergency visits, using linked pharmacy and medical claims alongside carefully selected comparisons. Smolak notes that claims data may not capture all care or patient experiences.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
